{"entity":{"id":"ionctura","kind":"company","name":"iOnctura","aka":[],"tldr":"iOnctura is a Switzerland-based biotechnology company running 2 late-stage cancer trials of roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma.","summary":"iOnctura, based in Geneva, Switzerland, is a biotechnology company. iOnctura is a biotech company developing precision oral small-molecule drugs that target the tumour-stroma-immune interface in neglected and hard-to-treat cancers. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing roginolisib in non-small-cell lung cancer, uveal melanoma and melanoma. The largest, NCT06717126 (A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma), plans to enrol 85 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ionctura.com"},{"label":"ClinicalTrials.gov: trials led by iOnctura","url":"https://clinicaltrials.gov/search?lead=iOnctura"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","uveal-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06717126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Geneva","country":"CH","companyType":"biotech","website":"https://www.ionctura.com","founded":2017,"stage":"growth","investors":[],"funding":[]},"route":"/companies/ionctura/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"trial":[{"id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/"},{"id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/"}],"company":[{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/"}],"drug":[{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/"}]}}